Loading

Fzata, Inc.

May 06, 2024
Session
Company Description: Fzata (fzata.com) has solved the oral biologics problem with the BIoPYM platform. Live yeast micro-factories make and secrete biologic therapeutic in the GI. Direct GI targeting avoids anti-drug antibody and systemic tox common to biologics like Humira which suffer upto a 50% discontinuation rate. We are an NIH Seed company with $17M non-dilutive. First in human clinical study will be 2024 for FZ002 c diff program fully supported by NIH. We are now raising seed $10M to support FZ006 IBD program. FZ006 will be the first oral anti-TNFalpha for IBD and also the first anti-TNFalpha for the mild-moderate IBD population. This is a multi-billion dollar market in the US alone and a huge unmet medical need.

Fzata, Inc.
View all SUS 2024

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS